| 產(chǎn)品描述： | Losmapimod (GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pKis of 8.1 and 7.6 for p38α and p38β, respectively |
| 靶點： |
pKi: 8.1 (p38α), 7.6 (p38β);p38MAPK;?Autophagy |
| 體內(nèi)研究： |
In the spontaneously hypertensive stroke-prone rat (SHR-SP), chronic treatment with GSK-AHAB significantly and dose-dependently improves survival, endothelial-dependent and -independent vascular relaxation, and indices of renal function, and it attenuates dyslipidemia, hypertension, cardiac remodeling, plasma renin activity (PRA), aldosterone, and interleukin-1β (IL-1β) |
| 參考文獻： |
1. Willette RN, et al. Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. J Pharmacol Exp Ther. 2009 Sep;330(3):964-70. 2. Zhang XM, et al. Suppression of mitochondrial fission in experimental cerebral ischemia: The potential neuroprotective target of p38 MAPK inhibition. Neurochem Int. 2015 Nov;90:1-8. |
| 溶解性： |
Ethanol : 33.33 mg/mL (86.92 mM; Need ultrasonic) DMSO : 27.5 mg/mL (71.72 mM; Need ultrasonic) |
| 保存條件： |
2-8℃ |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.608 ml |
13.039 ml |
26.078 ml |
| 5 mM |
0.522 ml |
2.608 ml |
5.216 ml |
| 10 mM |
0.261 ml |
1.304 ml |
2.608 ml |
| 50 mM |
0.052 ml |
0.261 ml |
0.522 ml |
|
| 注意： |
部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
危險品化學品經(jīng)營許可證（不帶存儲）
營業(yè)執(zhí)照(三證合一)
北京